Browse Newsroom

Insulife Appoints International Pharma Senior as Chief Pharmaceutical Governance Officer

August 16, 2021

We are very proud to announce that Silje Aubert has joined InsuLife AS as Chief Pharmaceutical Governance Officer (CPGO). “As we are experiencing speedy progress in our development path of our investigational spray-on-skin insulin delivery product, both in Europe and the US, we are excited to fill our Pharmaceutical Governance role with Silje, who brings valuable competence and experience to this important role in the company”, comments Aage Naerdal, Insulife CEO.

Silje brings a wealth of experience in pharmaceutical manufacturing from GSK and Roche where she has had the role as Qualified Person in both companies. She has had increasingly senior leadership roles over the years, including Head of medical Excellence and Quality, License to Operate Leader, Country Medical Lead and Medical transformation Lead. Most recently she was involved in an organization-wide transformation at Roche.

Academically, Silje has a Master’s degree in chemical engineering (biotechnology) from the Norwegian University of Science and Technology in Trondheim and an Executive MBA from Henley Business School, London. Having spent 18 years living and working in the UK, she has moved back to Norway with her family.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved